Physician profile
Gary G Leonhardt
NPI 1538183942
$91,631.26
in general payments reported to CMS, 2019-2025
27 companies · $20K in 2025
The $20K reported for 2025 was more than what 96% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $486 · 2021: $1,166 · 2022: $2,115 · 2023: $6,302 · 2024: $62K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Food and Beverage: $5,299 · Travel and Lodging: $2,086 · Honoraria: $1,625 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,200.00 |
| Food and Beverage | $5,299.24 |
| Travel and Lodging | $2,086.39 |
| Honoraria | $1,625.00 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $51,455.47 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Almatica Pharma LLC | $32,549.00 | 2024 | Loreev Xr |
| Abbvie INC. | $1,421.74 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $851.12 | 2019-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $628.18 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $539.53 | 2019-2023 | Rexulti, Abilify Maintena, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $529.37 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $501.78 | 2022-2025 | Auvelity |
| Alkermes, INC. | $481.41 | 2019-2024 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $429.36 | 2020-2025 | Caplyta |
| Allergan, INC. | $419.49 | 2019-2020 | |
| Indivior INC. | $368.56 | 2019-2023 | Perseris |
| Vanda Pharmaceuticals INC. | $328.44 | 2019-2023 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $245.86 | 2022-2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $169.39 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $136.27 | 2023 | Qelbree |
| Lundbeck LLC | $114.33 | 2019-2025 | Rexulti |
| Braeburn INC. | $90.07 | 2023-2024 | Brixadi |
| Eisai INC. | $89.44 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $66.82 | 2019-2020 | |
| Corium, LLC | $61.73 | 2023 | Azstarys |
| Jazz Pharmaceuticals INC. | $43.37 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $38.43 | 2022-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $28.61 | 2022-2023 | Trintellix |
| Brainsway USA INC | $18.03 | 2024 | Brainsway Deep Tms System |
| Kowa Pharmaceuticals America, INC. | $13.27 | 2022 | |
| Azurity Pharmaceuticals, INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Leonhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.